151406-36-9

Upstream product

• 204516-43-8 2,7-diethyl-6-hydroxymethyl-5-[[2'-(N-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole 
• 151406-81-4 2,7-diethyl-1H-pyrazolo[1,5-b][1,2,4]triazole-6-carboxyaldehyde 
• 151521-90-3 3-amino-4-ethyl-5-diethoxymethyl-1H-pyrazole 
• 161487-34-9 (2,7-Diethyl-1H-pyrazolo[1,5-b][1,2,4]triazol-6-yl)-methanol 
• 151521-91-4 N-(5-Diethoxymethyl-4-ethyl-1H-pyrazol-3-yl)-N'-hydroxy-propionamidine 

Downstream Products

• 204516-45-0 1-ethoxycarbonyloxyethyl 2,7-diethyl-5-[[2'-(N-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole-6-carboxylate 
• 204516-44-9 2,7-diethyl-5-[[2'-(N-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole-6-carboxylic acid 
• 151406-37-0 2,7-diethyl-5-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-5H-pyrazolo[1,5-b][1,2,4]triazole-6-carboxylic acid 

Relevant academic research and scientific papers

Studies on nonpeptide angiotensin II receptor antagonists. II. Synthesis and biological evaluation of 5H-pyrazolo[1,5-b][1,2,4]triazole derivatives with a C-linked oxygen functional group at the 6-position

2,7-Diethyl-5H-pyrazolo[1,5-b][1,2,4]triazole derivatives were synthesized and evaluated for activity as angiotensin II receptor antagonists. Replacement of the C-6 hydrogen with C-linked oxygen functional groups led to derivatives with increased in vitro